E815
TEAS SECTION 8 & 15 RECEIVED
06/23/2026
Back to search
Official data from USPTO
MEDINCELL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/24/2026
Trademark type
Word
Nice classes
5
Filing date
04/26/2019
Registration date
06/16/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2020
Last transaction
06/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Jacou, FR
Examiner
IM, JEAN H
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
MedinCell S.A.
Representatives
Stephen P. McNamara ST. ONGE STEWARD JOHNSTON & REENS LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical preparationsa drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparationsa drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; pharmaceutical compositions for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugssold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders
Publications
History of USPTO decisions and trademark events.
26 publications found
E815
TEAS SECTION 8 & 15 RECEIVED
06/03/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/16/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/31/2020
PUBO
PUBLISHED FOR OPPOSITION
03/31/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/11/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/27/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
02/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/31/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
01/31/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/31/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
01/31/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/31/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/08/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/10/2019
GNRT
NON-FINAL ACTION E-MAILED
07/10/2019
CNRT
NON-FINAL ACTION WRITTEN
07/10/2019
DOCK
ASSIGNED TO EXAMINER
07/09/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
05/23/2019
ALIE
ASSIGNED TO LIE
05/19/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/13/2019
NWAP
NEW APPLICATION ENTERED
04/30/2019
Continuous trademark protection
Get notified about every new filing that threatens MEDINCELL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.